In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...
By Rick Winterson Vertex Pharmaceuticals is a worldwide biotechnology corporation. It was founded 35 years ago in Cambridge. It has now established its global headquarters on Fan Pier in South ...
RBC Capital Markets analyst Bish Koziol made eight changes to his quantitatively driven top 40 list of stock picks. Maple ...
TrueFoundry, a startup offering enterprises a platform to deploy compound AI systems at scale, as raised $19 million in a ...
Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...
On Vertex's Q4 earnings call, investors will focus on management's comments about launch preparation for Alyftrek (vanza triple) and Journavx (suzetrigine).
Welbee, a multi-award-winning provider of survey solutions that support schools and trusts in gathering stakeholder feedback and managing their data efficiently ...
Vertex Bioenergy has secured long-term financing of approximately €350 million. The new platform financing streamlines the ...
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $470.37, marking a +1.88% move from the previous day.
Self-healing asphalt roads, made from biomass waste and designed with the help of artificial intelligence (AI), could offer a ...
One sickle cell patient told ITV News the new gene therapy being rolled out for use on the NHS means they "finally have something to look towards". | ITV National News ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback